Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides
drugs for the treatment of multiple sclerosis, nephrotic syndrome, and
infantile spasms indications. It primarily offers H.P. Acthar Gel, an
injectable drug for the treatment of acute exacerbations of multiple
sclerosis in adults; to induce a diuresis or a remission of proteinuria
in the nephrotic syndrome without uremia of the idiopathic type or that
due to lupus erythematosus; and as monotherapy for the treatment of
infantile spasms in infants and children under two years of age. The
company's H.P. Acthar Gel also focuses on rheumatology-related
conditions, including collagen diseases and rheumatic disorders. In
addition, it offers Doral for the treatment of insomnia. The company
sells its Acthar primarily to specialty pharmacies; and Doral to
pharmaceutical wholesalers. Questcor Pharmaceuticals, Inc. was founded
in 1990 and is headquartered in Anaheim, California.
To analyze the company's stock for potential trading opportunities,
please take a look at the 1-year chart of QCOR (Questcor
Pharmaceuticals, Inc.) below with my added notations:
After a nasty fall in September, QCOR has slowly worked its way
higher, one level at a time. From November through January the stock
created a clear level of support at $25 (green). Over the last (5)
months, QCOR has commonly reacted to the level of $30 (blue), both as
support and resistance. It has also not been uncommon for the stock to
find support or resistance at the $35 level (red). In summation, QCOR
primarily reacts to the increments of $5.
The Tale of the Tape: QCOR has broken below $30. A
short position could be entered at the $30 resistance with a stop placed
above that level. A long play could be made on a break above $30 with
an expectation of a rally up to $35.
Please share this article
No comments:
Post a Comment